Sangamo reports safety data from first MPS II patient in Phase I/II gene editing trial

Sangamo Therapeutics Inc. (NASDAQ:SGMO) reported initial safety data from the first patient with mucopolysaccharidosis II (MPS II, Hunter’s syndrome) who received a single IV infusion of SB-913 in

Read the full 282 word article

User Sign In